Davis Polk advised the underwriters in connection with an initial public offering of 9,250,000 shares of common stock of Alector, Inc. at $19.00 per share, for total gross proceeds of $175.8 million. The common stock is listed on the NASDAQ Global Select Market under the symbol “ALEC.”
Headquartered in South San Francisco, California, Alector is a clinical stage biotechnology company pioneering immuno-neurology, a novel therapeutic approach for the treatment of neurodegeneration.
The Davis Polk corporate team included partners Alan F. Denenberg and Stephen Salmon and associates Dongbiao Shen and Kimberly Wang. Partner Frank J. Azzopardi and associates Michael V. Policastro and Hilary Smith provided intellectual property and technology advice. The tax team included partner Rachel D. Kleinberg and associate Rebecca A. Rosen. Counsel Marcie A. Goldstein provided FINRA advice. Members of the Davis Polk team are based in the Northern California and New York offices.